Economy/Home · Economy

Celltrion Rises as KB Securities Raises Target Price 11% to 300,000 Won, Names It 'Top Pick'

Celltrion was on an uptrend during intraday trading on the 3rd, trading in the 190,000-won range. In the securities industry, there is a growing movement to re-evaluate Celltrion's corporate value, based on its earnings stability and the growth potential of the biosimilar market. In particular, the

Wooil Shim
Staff Reporter
6 min read
Celltrion Rises as KB Securities Raises Target Price 11% to 300,000 Won, Names It 'Top Pick'
CBC News

Celltrion was on an uptrend during intraday trading on the 3rd, trading in the 190,000-won range. In the securities industry, there is a growing movement to re-evaluate Celltrion's corporate value, based on its earnings stability and the growth potential of the biosimilar market. In particular, the fact that the company has delivered results that met or exceeded market expectations for four consecutive quarters is cited as a positive factor.

In the stock market on the 3rd, Celltrion traded at 193,500 won, up 1,500 won from the previous trading day, a 0.78% increase.

KB Securities maintained its 'Buy' investment opinion on Celltrion while raising its target price by 11% from the previous level to 300,000 won. It also designated Celltrion as its Top Pick.

The target price increase reflects assessments of the company's performance and industry conditions. KB Securities noted that Celltrion has recorded results that met or exceeded market forecasts for four consecutive quarters, which was presented as a key basis for evaluating future earnings, indicating that quarterly results have consistently met market expectations.

The growth trend of the biosimilar industry also influenced the target price hike. KB Securities assessed that the biosimilar market is entering a full-fledged growth phase. In particular, it analyzed that with the industry's so-called 'mega cycle' beginning, visibility into Celltrion's mid- to long-term earnings growth has improved compared to before. Biosimilars are medicines developed to be highly similar to existing biopharmaceuticals, and the expansion of the related market is linked to growth prospects for companies with business foundations in the field.

KB Securities comprehensively considered these industry changes and Celltrion's earnings trends in raising its target price.

The difference between the intraday share price of 193,500 won and KB Securities' target price of 300,000 won is 106,500 won. However, a securities firm's target price is merely a figure reflecting its evaluation of future corporate value and does not mean the actual share price will reach that level.

As Celltrion shows an upward trend in the 190,000-won range, whether future earnings meet market expectations and whether the biosimilar business's growth momentum continues remain key points to watch.

[This article was written based on intraday share prices and securities firm analysis and does not recommend buying or selling any specific stock. Securities firms' target prices and earnings forecasts may change depending on market conditions and corporate management situations. Stock investment carries the risk of principal loss, and investment decisions and responsibility rest with the investor. AI assisted in part.]

Wooil Shim
Staff Reporter

CBC Globe publishes verified stories with editorial review, source checks, and tenant-specific publication standards.